KOD
Kodiak Sciences Inc.
Biotechnology
Market Cap$2.31B
5Y Perf.+238.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
KOD vs RGNX
Revenue, margins, valuation, and 5-year total return — side by side.
RGNX
REGENXBIO Inc.
Biotechnology
Market Cap$527M
5Y Perf.-72.3%
KOD vs RGNX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KOD | RGNX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $2.31B | $527M |
| Revenue (TTM) | $0.00 | $161M |
| Net Income (TTM) | $-217M | $-178M |
| Gross Margin | — | 50.0% |
| Operating Margin | — | -96.0% |
| Total Debt | $70M | $82M |
| Cash & Equiv. | $168M | $58M |
KOD vs RGNX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KOD
RGNX
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | 100 | 338.1 | +238.1% |
| REGENXBIO Inc. (RGNX) | 100 | 27.7 | -72.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KOD vs RGNX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KOD leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. REGENXBIO Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
KOD
Kodiak Sciences Inc.
The Income Pick
KOD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.81
- EPS growth 32.6%
- 20.5% 10Y total return vs RGNX's 5.4%
Best for: income & stability and growth exposure
RGNX
REGENXBIO Inc.
The Growth Leader
RGNX is the clearest fit if your priority is growth and efficiency.
- -7.7% revenue growth vs KOD's -15.7%
- -33.9% ROA vs KOD's -99.7%, ROIC -53.8% vs -130.7%
Best for: growth and efficiency
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RGNX | -7.7% revenue growth vs KOD's -15.7% |
| Quality / Margins | KOD | 3.3% margin vs RGNX's -110.3% |
| Stability / Safety | KOD | Beta 1.81 vs RGNX's 2.59 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | KOD | +10.3% vs RGNX's +43.9% |
| Efficiency (ROA) | RGNX | -33.9% ROA vs KOD's -99.7%, ROIC -53.8% vs -130.7% |
KOD vs RGNX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
KOD vs RGNX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKODLAGGINGRGNX
RGNXREGENXBIO Inc.
2leads
KODKodiak Sciences Inc.
2leads
6 Total Categories
CATEGORYLEADERvs RGNXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RGNX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RGNX5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
KOD6/6
Risk & VolatilityBeta, volatility, and downside exposure
KOD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RGNX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RGNX and KOD operate at a comparable scale, with $161M and $0 in trailing revenue.
| Metric | KODKodiak Sciences I… | RGNXREGENXBIO Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $161M |
| EBITDAEarnings before interest/tax | -$195M | -$139M |
| Net IncomeAfter-tax profit | -$217M | -$178M |
| Free Cash FlowCash after capex | -$127M | -$106M |
| Gross MarginGross profit ÷ Revenue | — | +50.0% |
| Operating MarginEBIT ÷ Revenue | — | -96.0% |
| Net MarginNet income ÷ Revenue | — | -110.3% |
| FCF MarginFCF ÷ Revenue | — | -65.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +22.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -38.1% | -2.6% |
RGNX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — KOD and RGNX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | KODKodiak Sciences I… | RGNXREGENXBIO Inc. |
|---|---|---|
| Market CapShares × price | $2.3B | $527M |
| Enterprise ValueMkt cap + debt − cash | $2.2B | $552M |
| Trailing P/EPrice ÷ TTM EPS | -13.04x | -2.27x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 6.33x |
| Price / BookPrice ÷ Book value/share | 15.28x | 1.99x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — KOD and RGNX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
RGNX leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
RGNX delivers a -110.2% return on equity — every $100 of shareholder capital generates $-110 in annual profit, vs $-9 for KOD. RGNX carries lower financial leverage with a 0.32x debt-to-equity ratio, signaling a more conservative balance sheet compared to KOD's 0.47x. On the Piotroski fundamental quality scale (0–9), RGNX scores 4/9 vs KOD's 3/9, reflecting mixed financial health.
| Metric | KODKodiak Sciences I… | RGNXREGENXBIO Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -9.2% | -110.2% |
| ROA (TTM)Return on assets | -99.7% | -33.9% |
| ROICReturn on invested capital | -130.7% | -53.8% |
| ROCEReturn on capital employed | -50.0% | -57.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.47x | 0.32x |
| Net DebtTotal debt minus cash | -$98M | $25M |
| Cash & Equiv.Liquid assets | $168M | $58M |
| Total DebtShort + long-term debt | $70M | $82M |
| Interest CoverageEBIT ÷ Interest expense | — | -3.22x |
RGNX leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
KOD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KOD five years ago would be worth $21,496 today (with dividends reinvested), compared to $2,873 for RGNX. Over the past 12 months, KOD leads with a +1028.7% total return vs RGNX's +43.9%. The 3-year compound annual growth rate (CAGR) favors KOD at 107.8% vs RGNX's -17.3% — a key indicator of consistent wealth creation.
| Metric | KODKodiak Sciences I… | RGNXREGENXBIO Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +67.9% | -23.2% |
| 1-Year ReturnPast 12 months | +1028.7% | +43.9% |
| 3-Year ReturnCumulative with dividends | +796.9% | -43.5% |
| 5-Year ReturnCumulative with dividends | +115.0% | -71.3% |
| 10-Year ReturnCumulative with dividends | +2051.7% | +5.4% |
| CAGR (3Y)Annualised 3-year return | +107.8% | -17.3% |
KOD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
KOD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KOD is the less volatile stock with a 1.81 beta — it tends to amplify market swings less than RGNX's 2.59 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KOD currently trades 91.3% from its 52-week high vs RGNX's 64.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KODKodiak Sciences I… | RGNXREGENXBIO Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.81x | 2.59x |
| 52-Week HighHighest price in past year | $47.84 | $16.19 |
| 52-Week LowLowest price in past year | $2.81 | $6.89 |
| % of 52W HighCurrent price vs 52-week peak | +91.3% | +64.4% |
| RSI (14)Momentum oscillator 0–100 | 61.7 | 64.5 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 741K |
KOD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates KOD as "Buy" and RGNX as "Buy". Consensus price targets imply 147.1% upside for RGNX (target: $26) vs 48.1% for KOD (target: $65).
| Metric | KODKodiak Sciences I… | RGNXREGENXBIO Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $64.67 | $25.75 |
| # AnalystsCovering analysts | 18 | 20 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.2% |
Insufficient data to determine a leader in this category.
Key Takeaway
RGNX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). KOD leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Best OverallKodiak Sciences Inc. (KOD)Leads 2 of 6 categories
Loading custom metrics...
KOD vs RGNX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is KOD or RGNX a better buy right now?
Analysts rate Kodiak Sciences Inc.
(KOD) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KOD or RGNX?
Over the past 5 years, Kodiak Sciences Inc.
(KOD) delivered a total return of +115. 0%, compared to -71. 3% for REGENXBIO Inc. (RGNX). Over 10 years, the gap is even starker: KOD returned +20. 5% versus RGNX's +5. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KOD or RGNX?
By beta (market sensitivity over 5 years), Kodiak Sciences Inc.
(KOD) is the lower-risk stock at 1. 81β versus REGENXBIO Inc. 's 2. 59β — meaning RGNX is approximately 43% more volatile than KOD relative to the S&P 500. On balance sheet safety, REGENXBIO Inc. (RGNX) carries a lower debt/equity ratio of 32% versus 47% for Kodiak Sciences Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — KOD or RGNX?
On earnings-per-share growth, the picture is similar: Kodiak Sciences Inc.
grew EPS 32. 6% year-over-year, compared to 23. 8% for REGENXBIO Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — KOD or RGNX?
Kodiak Sciences Inc.
(KOD) is the more profitable company, earning 0. 0% net margin versus -272. 5% for REGENXBIO Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KOD leads at 0. 0% versus -280. 0% for RGNX. At the gross margin level — before operating expenses — RGNX leads at 59. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — KOD or RGNX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is KOD or RGNX better for a retirement portfolio?
For long-horizon retirement investors, Kodiak Sciences Inc.
(KOD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. REGENXBIO Inc. (RGNX) carries a higher beta of 2. 59 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KOD: +20. 5%, RGNX: +5. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between KOD and RGNX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.